Molecular PharmaGroup
FDA 503B outsourcing facility
New Providence, New Jersey
Key Takeaways
- FDA-registered 503B outsourcing facility since 2018
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: August 11, 2025
- FDA action: Untitled Letter Issued 2/5/2026
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- May 8, 2018
- Most recent registration
- December 30, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- August 11, 2025
The FDA last inspected Molecular PharmaGroup on August 11, 2025. Investigators issued a Form FDA 483 listing inspectional observations at that visit. FDA action on record: Untitled Letter Issued 2/5/2026.
What this facility compounds
Molecular PharmaGroup reports compounding 1 distinct active ingredient to the FDA Outsourcing Facility Product Report (most recent reporting periods).
- Dehydrated Alcohol
Contact
FDA-registered contact: Amanda Lanze, 908-588-3440. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Molecular PharmaGroup with the New Jersey Board of Pharmacy.
503B facilities in New Jersey
New Jersey has 10 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in New Jersey.
Frequently asked questions
Is Molecular PharmaGroup registered with the FDA?
Yes. Molecular PharmaGroup is a registered 503B outsourcing facility, first registered with the FDA on May 8, 2018 and most recently registered on December 30, 2025.
Has Molecular PharmaGroup been inspected by the FDA?
The FDA last inspected Molecular PharmaGroup on August 11, 2025. A Form FDA 483 was issued. FDA action on record: Untitled Letter Issued 2/5/2026.
Has Molecular PharmaGroup had any FDA drug recalls?
No FDA drug recalls are matched to Molecular PharmaGroup in the openFDA enforcement database.
What does Molecular PharmaGroup compound?
Molecular PharmaGroup reports compounding 1 active ingredient to the FDA.
Where is Molecular PharmaGroup located?
Molecular PharmaGroup is located in New Providence, New Jersey.
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Molecular PharmaGroup. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.